RxDoctor Payments Data

Joymon Sebastian, NP

Family · Dartmouth, MANPI 1437668241

Payments from drug & device makers

$2,332in general payments, 2019–2025

Across 27 payments — averaging $86.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Amgen$177
  • Insulet Corporation$138
  • Bayer$125
  • Boehringer Ingelheim$125
  • AstraZeneca$114
  • plus $258 from 6 others

What the payments were for

  • Travel & lodging$1,17750%
  • Food & beverage$1,15550%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,332 in reported general payments places this provider in the 90th percentile of 2,320 family providers in Massachusetts.

See all family providers in Massachusetts

Medicare billing

Part B allowed, 2024
$86,446
Medicare patients
325
Services billed
2,683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide889$1,095,473
JardianceEmpagliflozin653$783,812
OzempicSemaglutide381$494,130
MounjaroTirzepatide270$304,728
JanuviaSitagliptin Phosphate187$214,467
FarxigaDapagliflozin Propanediol148$171,960
Humulin R U-500 KwikpenInsulin Regular, Human81$137,948
TradjentaLinagliptin100$93,467
RybelsusSemaglutide41$78,670
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog144$66,013
Bydureon BciseExenatide Microspheres56$56,935
Lantus SolostarInsulin Glargine,hum.Rec.Anlog370$44,662
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp146$39,443
Tresiba Flextouch U-100Insulin Degludec42$36,803
Fiasp FlextouchInsulin Aspart (Niacinamide)32$26,324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humalog Mix 75-25$22$1,407,7521,192 claims
Boehringer IngelheimJardiance, Tradjenta$125$877,279753 claims
Novo NordiskOzempic, Rybelsus, Novolog Mix 70-30, Novolog$57$585,332459 claims
AstraZenecaFarxiga$114$171,960148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,320 family providers in Massachusetts.

Other family in Dartmouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →